Although numerous cartilage engineering methods have been described, few report generation of constructs greater than 4 cm 2 , which is the typical lesion size considered for cell-based therapies. Furthermore, current cell-based therapies only target focal lesions, while treatment of large non-isolated lesions remains an area of great demand. The constructs, respectively. This study not only demonstrated that exceedingly large selfassembled neocartilage can be generated with the appropriate combination of mechanical and chemical stimuli, but that its properties were maintained or even enhanced.
Introduction
Tissue engineering approaches have potential to overcome the shortcomings of clinically used cartilage repair options. In the Unites States, an estimated 250,000 articular cartilage repair procedures are performed annually (1) . Despite their prevalence, current repair therapies do not consistently fill the entire defect, and the repair tissue produced is not hyaline and does not integrate with the surrounding native tissue. Microfracture has been shown to form a biomechanically inferior, fibrocartilaginous repair tissue, leading to repair tissue deterioration after 1.5-5 years (2) (3) (4) (5) . Mosaicplasty with osteochondral autografts or allografts has been reported to fail in 15-55% of patients after 10 years (6) (7) (8) . Reasons include failure at the osseous region, poor lateral integration, and deterioration of graft edges. Auto/allografts also have a limited supply source. Finally, results from autologous chondrocyte implantation (ACI) can be inconsistent; up to 85% of treated defects developed fibrocartilaginous fill (9) (10) (11) . These inconsistencies may arise from the uncontrolled placement of cells and an in situ neocartilage maturation process that is dependent on patient biology and post-surgery activities. To overcome these problems, tissue engineering strategies need to be developed so that engineered neocartilage constructs may be consistently engineered to have functional hyaline-like matrix and with anatomically relevant dimensions.
In a study investigating 25,000 knee arthroscopies, the majority of chondral lesions (70%) were shown to be non-isolated lesions (i.e., defined as having four or more focal lesions) (12) . Treatment algorithms based on lesion size suggest the use of microfracture and osteochondral autografts for small focal lesions less than 2-2.5 cm 2 (8, 13) .
Microfracture is generally indicated for small defects, as the biomechanically inferior repair tissue requires a border of native tissue for mechanical support. The size of osteochondral autografts is limited to minimize donor site morbidity. Osteochondral allografts and ACI have been recommended to treat lesions greater than 2-2.5 cm 2 (8, 13) and, on average, treat focal lesions 4 cm 2 (14) . Even tissue engineered cartilage products currently in clinical trials, representing the next generation therapies, limit their clinical indications to focal defects less than 7.5 cm 2 (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Large, non-isolated defects generally receive palliative treatment until total or partial knee arthroplasty is indicated. Therefore, This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
a tissue engineering approach that bridges the treatment of focal defects and total joint arthroplasty remains an unmet need for the foreseeable future. The next step in cartilage tissue engineering would involve fabricating constructs not only with functional properties but also of sufficient size to treat cartilage lesions of all sizes.
Engineered neocartilage with hyaline-like matrix composition and functional biomechanical properties has been fabricated using the self-assembling process (25, 26) . In the self-assembling process, articular chondrocytes (ACs) are seeded at high density in non-adherent agarose wells (27, 28) . Recently, passaged ACs were used as a cell source in fabricating these neocartilage constructs (25, 29, 30) . ACs underwent chondrotuning expansion (29) and aggregate redifferentiation to enhance redifferentiation of the dedifferentiated chondrocytes (30, 31) . With these cells, it was shown that 2 million cells per 5 mm dia. disc allowed the formation of homogeneous tissues with a hyaline-like matrix (abundant type II collagen; little to no type I collagen) and tensile properties near those of juvenile articular cartilage (25) .
A significant scale-up of the self-assembling process would be necessary to generate neocartilage constructs of sizes that can broadly treat all types of articular lesions. Currently, most self-assembled neocartilage constructs are formed with an initial diameter of 5 mm that may grow to at most 7 mm, or 0.4 cm 2 in area. One challenge of designing a large construct is diffusion limitations. Although diffusion in the axis of cartilage thickness may be similar in both the small and large constructs, radial diffusion will be severely limited when scaling-up to large constructs, potentially adversely affecting construct biomechanical properties or matrix composition. Another challenge is maintaining shape fidelity when growing large neotissues, as shown in this study. The logistics of creating a large construct, from chondrocyte passaging to mold fabrication, may also pose unforeseen challenges. Thus, scaling up the self-assembling process may not be a simple or straightforward process and should be investigated as a critical step in pushing the technology toward broad clinical application. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
chondroitinase-ABC (C-ABC), and lysyl oxidase like 2 (LOXL2) protein), which had been originally developed in 5 mm dia. self-assembled neocartilage constructs, may not necessarily induce the same effects in scaled-up constructs because of diffusion limitations or other unforeseen variables. TGF-β1 is an anabolic factor known to promote chondrogenesis and enhance GAG and type II collagen synthesis (32, 33) . C-ABC acts by temporarily depleting GAGs in the constructs, restructuring the matrix to allow the development of a matrix richer in collagens and allowing formation of thicker collagen fibers (34) . LOXL2 was not shown to effect neocartilage matrix content, but was able to increase tissue tensile properties through increasing the number of pyridinoline collagen cross-links (26) . Cytochalasin D, a potent inhibitor of intracellular actin stress fiber formation, has been shown to induce a rounded cell phenotype and chondrogenesis in stem cells (35) . Although these chemical stimuli have been shown to enhance neocartilage properties in "small" constructs, whether they can enhance properties in "large"
constructs is an important criterion in successfully scaling-up the self-assembling process.
The motivation of using young ACs in this study is that they have a superior capability to secrete cartilage matrix molecules compared to adult chondrocytes or stem cells that have been expanded (36) . Young chondrocytes have also been shown to have significantly higher collagen II gene expression (36, 37) and drastically higher GAG production than adult chondrocytes (36, 38) . In order to scale-up construct fabrication, cell expansion will be necessary. A cell source capable of maintaining its chondrogenic phenotype after expansion will be critical for the generation of functional cartilage.
Allogeneic chondrocytes have also been shown to be non-immunogenic (39 This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
ABC, and LOXL2). The hypothesis was that there would be no difference in the functional properties between the established model of self-assembled neocartilage formation (i.e., 5 mm dia. constructs) and a significantly scaled-up version (i.e., 25 mm dia. constructs).
Constructs of both diameters were formed with or without chemical stimulation, and, at the end of 6 weeks of culture, constructs were evaluated grossly, biochemically, and mechanically. Scaling-up the self-assembling process to such a size would enable its broad use in cartilage repair by treating a large range of lesion sizes.
Materials and Methods

Chondrogenic medium formulation
The chondrogenic medium used throughout the study comprised of DMEM (25 
Chondrocyte passaging
Primary ACs underwent chondrotuning expansion in monolayer to passage 4 (P4), as previously described (29), with some modifications. Briefly, P0 ACs were thawed and with a hemocytometer, and either passaged again into monolayer (as described above) or into aggregate culture, as describe next.
Aggregate culture
Passaged ACs underwent aggregate redifferentiation, as previously described (30, 31) .
Briefly, 10 cm petri dishes were first coated with a thin layer of 2% molten agarose to prevent cell adhesion. In each dish, 25 million cells in 25 mL chondrogenic medium supplemented with 10 ng/mL TGF-β1, 100 ng/mL BMP-2, and 100 ng/mL GDF-5 (Peprotech). Dishes were put on an orbital shaker at 55 rpm for 24 h and then cultured statically for an additional 13 days. Medium was changed every 2-3 days. At day 14, cell aggregates were digested with 0.25% trypsin/EDTA for 20 min, the trypsin removed, and then digested in 500 units/mL collagenase in chondrogenic medium + 3% FBS for 90-120 min. Cells were filtered through a 70 µm cell strainer, washed three times, counted, and used for the self-assembly of neocartilage constructs.
Self-assembly of neocartilage constructs
Scaffold-free neocartilage constructs, formed via the self-assembling process (27) , were generated by seeding ACs into 2% agarose wells with an inner diameter of 5 or 25 mm.
Custom-machined, 5 mm diameter stainless steel posts were used as negative casts to create agarose self-assembly wells in 750 µL of 2% agarose in each well within a 48-well plate. Agarose wells, 25 mm in diameter, were also created using a mold system consisting This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
of 3D-printed parts (printed with an Objet system using MED610 or Vero White materials;
Stratasys, Eden Prairie, MN). All agarose wells were saturated with several changes of chondrogenic medium for 5 days before cell seeding.
To form 5 mm diameter neocartilage constructs, 2 million cells in 80 µL chondrogenic medium were seeded into empty 5 mm diameter agarose wells. After a 4 h incubation, 500 μL medium was carefully added to each well so as to not disturb the nascent construct (t=0 days). Every 24 h, 500 μL medium was changed. At day 2, constructs were unconfined and placed into 10.5 mm diameter, 2% agarose wells (formed by using 3D-printed pegs as a negative cast) in 24-well plates. Every 48 h, 1 mL of medium was changed. At day 4, an agarose disc (10 mm diameter by 2 mm thick, formed by a mold system consisting of 3D-printed parts) was added to the top of each construct, followed by addition of an 8 mm diameter, 7 mg plastic deadweight (taking in account buoyancy in water; printed with MED610). The deadweight was only applied every other day until Day 21 and from Days 28-35.
To form 25 mm diameter constructs, 50 million cells in 2 mL medium were seeded into empty 25 mm diameter agarose wells placed on top of 3D-printed plastic stands ( Figure 1A) . The agarose wells and stands were housed in 10 cm diameter, 2.5 cm tall petri dishes. The plastic stands served to enhance nutrient diffusion. After a 4 h incubation, 2 mL medium was carefully added to cover the agarose well. A 3D-printed plastic weight was placed on top of the agarose well to prevent it from excessively moving during handling. At day 2, constructs were unconfined and placed into 35 mm diameter, 2% agarose wells (formed by using a mold system of 3D-printed parts) in petri dishes. It was known that constructs would begin developing a curled morphology ( Figure 1B ). To maintain a flat morphology, at day 4, a 33 mm diameter, 2.5 mm thick agarose disc (formed by a mold system consisting of 3D-printed parts) was added to the top of each construct, followed by addition of a 30 mm diameter, 175 mg plastic deadweight (taking in account buoyancy in water; printed with MED610; Figure 1C ). The deadweight was applied at the same temporal regimen as for the 5 mm constructs. Every 5-6 days, 60 mL of medium was changed. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
After 42 days, constructs were photographed and their wet weights were recorded.
Each construct was then assayed via histology, and biochemical and biomechanical assays .
Chemical stimulation treatment
For groups subjected to chemical stimulation treatment, 2 µM cytochalasin D (Enzo Life Sciences, Farmingdale, NY) was supplemented to the medium at Days 0-3; 10 ng/mL TGF-β1 was supplemented throughout culture (Days 0-42); LOXL2 cocktail was supplemented at Days 21-42 (LOXL2 cocktail consisted of 0.15 µg/mL lysyl oxidase-like 2 (LOXL2) protein (Genway Bio, San Diego, CA) + 1.6 µg/mL copper sulfate (Sigma) + 146 µg/mL hydroxylysine (Sigma)); and 2U/mL chondroitinase ABC (C-ABC; Sigma), activated with 0.05M sodium acetate (Sigma), was applied for 4 h at Day 21 ( Figure 1D ). After C-ABC application, constructs were washed with chondrogenic medium containing 1 mM zinc sulfate (Sigma) three times to deactivate and remove residual C-ABC.
Histology and immunohistochemistry
Tissue samples (~1x1x1 mm) were embedded in HistoPrep (Thermo Fisher Scientific) and cryosectioned to 16 μm thick sections and mounted on glass slides. Staining for GAGs was performed with Safranin O, Fast Green, and Weigert's hematoxylin. Collagen staining was performed with picrosirius Red. Collagen I and II immunohistochemistry were also performed, as described previously (40) . Color was developed using the Vectastain ABC reagents and DAB (Vectastain).
Biochemical analysis
Neocartilage samples, ~3x1x1 mm (approx. 5-12 mg) were weighed to obtain wet weights (WW), lyophilized for 3 days, and weighed again to obtain dry weights (DW). Samples were digested in digest solution consisting of 125 µg/mL papain + 5 mM N-acetyl-L-cysteine + 5 mM EDTA in phosphate buffer, pH 6.5.
Total collagen content was measuring using a modified chloramine-T colorimetric 
Biomechanical analysis
For tensile testing, dog bone-shaped samples were cut from each engineered construct.
The dog bone samples were then photographed, glued to paper tabs with a gauge length of 1.27 mm, and underwent uniaxial tension using an Instron model 5565 (Instron, Canton, MA) (42) . A strain rate of 1% the gauge length/s was used. Sample cross-sectional areas were calculated in ImageJ from high-resolution photographs of the dog bone. The Young's modulus was obtained from the linear region of the stress-strain curve and the ultimate tensile strength (UTS) was defined as the maximum stress obtained.
For compressive testing, a 3 mm diameter sample was taken from the middle of each engineered construct with a biopsy punch. The sample was placed in a PBS bath at room temperature and underwent unconfined stress-relaxation, as described previously (43) . Sample heights were determined by lowering the platen until a load change of 0.02 N was detected. Samples were then compressed to 10% strain at a rate of 1% the sample This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
height/s, held for 200 s, compressed to 20% strain, and held for 450 s. The instantaneous and relaxation moduli of the 20% strain curve were determined by using a curve fit and the standard linear solid (SLS), finite deformation (FD) model (43) using MatLab software.
Statistics
All results were analyzed with a one-factor ANOVA and Tukey's post hoc test (p<0.05) using JMP 10 software (SAS Institute). Data are presented as means, and error bars represent standard deviations among biological replicates within the same group. A sample size of n=6-8 per group was used. Significant differences are indicated by different letters by each value.
Results
Neocartilage Gross Morphology
The gross morphological properties of the self-assembled neocartilage constructs after 6
weeks of culture are presented in The thicknesses of all constructs were generally slightly less than 1 mm. Chemical stimulation reduced the thickness of both 5 mm and 25 mm constructs, though only significantly so for the 25 mm constructs. Regional analysis of the 25 mm constructs showed significantly thicker edges than the center.
Histology and Immunohistochemistry
Saf-O/Fast Green and Picrosirius Red staining revealed the abundant presence of GAGs and collagen, respectively, throughout the neocartilage constructs (Figure 3) . Differences in staining intensity and staining distribution were not observed among any groups.
Immunohistochemistry revealed presence of type II collagen throughout all constructs.
Collagen I immunohistochemical staining revealed only trace amounts of collagen type I. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Histological characteristics qualitatively support the formation of hyaline-like cartilage in all constructs.
Neocartilage Biochemical Properties
Collagen content, as measured by collagen per wet weight (collagen/WW), was not different between the unstimulated 5 mm and unstimulated 25 mm constructs (Figure 4) . 
Neocartilage Biomechanical Properties
The tensile properties, as measured by the Young's modulus and the UTS, were not different between the unstimulated 5 mm and unstimulated 25 mm constructs ( Figure 5 ).
Interestingly, chemical stimulation increased the tensile properties of the 25 mm constructs (240% increase in Young's modulus; 500% increase in UTS) more than that of the 5 mm constructs (70% increase in Young's modulus; 140% increase in UTS). This led to the 25 mm stimulated constructs having significantly higher tensile properties than that of 
Discussion
Toward addressing the current need to repair large or non-isolated cartilage defects, which represent the majority of lesions in patients, the objectives of the study were: 1) To fabricate scaffold-free neocartilage greater than 8 cm 2 by scaling-up the self-assembling This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. stimulated 5 mm dia. constructs by 70%, 140%, and 30% over unstimulated controls; in the 25 mm dia. constructs, these same properties were increased even further -240%, 510%, and 140% -over controls. This study showed that significant scale-up of the selfassembling process is possible and that neocartilage functional properties can be maintained or even enhanced in the process. Fabrication of large functional neocartilage provides a key step toward potentially treating large or non-isolated lesions, bridging the gap between current repair therapies and knee arthroplasty and pushing cartilage tissue hyaluronic acid hydrogels, also exhibited edge effects (47) . After 12 weeks of culture, the center of the constructs had significantly lower collagen and GAG content and mechanical properties than the edges. The difference was attributed to potential diffusion limitations.
In this study, the center of the constructs did not have inferior properties compared to This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
those of the edge regions. Overall, the fabrication protocols described in this study allowed formation of large constructs with properties similar to those of the small constructs.
This study demonstrated the feasibility of generating functional neocartilage greater than 8 cm 2 without compromising its properties. These constructs can potentially be used to treat a broader range of cartilage lesion sizes compared to current therapies.
Among current cartilage repair options, microfracture or osteochondral autografts have been stated to optimally treat lesions less than 2-2.5 cm 2 in area (8, 13) . Above this size, cell-based therapies, such as ACI, tissue engineered products, and osteochondral allografts have been used to treat focal defects that are generally less than 7.5 cm 2 (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) ; the average size of lesions treated by ACI and osteochondral allografts is 4 cm 2 (14) . However, 70% of cartilage lesions have been shown to be non-isolated lesions (12) which often exceed sizes larger than 7.5 cm 2 . The large constructs generated in this study did not exhibit significant decreases in biochemical or functional biomechanical properties; in fact, some properties were enhanced during scale-up. With the current demonstration that such large neocartilage constructs can be fabricated, the next developmental phase would be to create anatomically correct morphologies. Functional neocartilage of these sizes can potentially treat large or non-isolated lesions. Repair therapy using these scaled-up constructs can potentially bridge the gap between current therapies that only treat focal defects and total or partial knee arthroplasty.
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